Business Context and Reporting Period
Company: InMed Pharmaceuticals Inc. (Nasdaq: INM)
Filing Type: Form 10-Q (Unaudited)
Reporting Period: Three months ended September 30, 2025
Business Overview: InMed is a pharmaceutical drug development company with two reportable segments: Pharma (R&D of small molecule drug candidates for Alzheimer's, dry AMD, and Epidermolysis Bullosa) and Commercial (BayMedica LLC, manufacturing and selling bulk rare cannabinoids for the health and wellness sector). The company is incorporated in British Columbia, Canada, and operates as a smaller reporting company and emerging growth company.
Key Financial Metrics
| Metric | Q1 2025 (3 Months Ended Sept 30) | Q1 2024 (3 Months Ended Sept 30) |
|---|---|---|
| Revenue (Sales) | $1,120,121 | $1,264,638 |
| Gross Profit | $403,159 | $493,413 |
| Gross Margin | 36.0% | 39.0% |
| Net Loss | $(1,726,899) | $(1,677,868) |
| Net Loss Per Share (Basic & Diluted) | $(0.44) | $(2.71) |
| Cash and Cash Equivalents | $9,331,077 | $5,583,039 |
| Total Current Assets | $10,799,967 | $12,867,279 |
| Total Current Liabilities | $1,554,984 | $1,839,790 |
| Accumulated Deficit | $(118,964,791) | $(110,753,627) |
| Cash Used in Operating Activities | $(1,607,616) | $(1,826,810) |
Material Changes vs. Prior Period
- Revenue Decline: Total sales decreased by 11% ($145,000) year-over-year. The Commercial segment reported a decline driven by lower product pricing due to increased competition. The Pharma segment generated no revenue.
- Expense Management: Total operating expenses remained relatively flat at approximately $2.22 million.
- Pharma Segment: R&D expenses decreased 17% due to reduced external contractor and supply costs, partially offset by higher personnel compensation.
- Commercial Segment: General and administrative expenses increased 59% due to higher salaries, benefits, and marketing expenses.
- Liquidity Position: Cash and cash equivalents increased by approximately $3.7 million compared to the prior year period, though cash decreased by $1.7 million during the current quarter due to operating losses.
- Share Count: Weighted average shares outstanding increased significantly from 620,127 in Q1 2024 to 3,954,549 in Q1 2025, primarily due to the exercise of pre-funded warrants and share issuances, diluting the loss per share impact.
Outlook, Risks, and Contingencies
Going Concern Warning
Management has concluded there is substantial doubt about the Company's ability to continue as a going concern for one year following the issuance of these financial statements. The company has incurred recurring losses and negative cash flows since inception. While current cash reserves ($9.4 million) are projected to fund operations into the fourth quarter of 2026, future viability depends on raising additional capital.
Legal Proceedings (Material Contingency)
Patent License Matter: BayMedica is involved in arbitration with a third-party Licensor regarding a technology license agreement.
- Claim: The Licensor asserts that annual royalty payments are guaranteed minimums regardless of net sales.
- Exposure: The Licensor seeks approximately $3.4 million in payments for 2022–2024 and a declaration of liability for approximately $2.3 million annually for the remainder of the agreement term.
- Impact: An unfavorable outcome could have a material adverse impact on the Company's financial condition and BayMedica's ability to continue operations.
Outlook and Strategy
- R&D Pipeline: Continued focus on INM-901 (Alzheimer's), INM-089 (dry AMD), and INM-755 (Epidermolysis Bullosa). Preclinical data for INM-901 was presented at the AAIC 2025 conference.
- Commercial Strategy: BayMedica will evaluate structured supply arrangements and collaborations while focusing on high-margin products.
- Capital Needs: The Company expects to seek additional funding through equity or debt financings, collaborations, or strategic transactions.
Investor Verification Checklist
- Going Concern Status: Verify the timeline for the next capital raise and the sufficiency of the $9.4 million cash runway against projected burn rates.
- Arbitration Outcome: Monitor the status of the Patent License Matter arbitration, as a loss could trigger immediate liabilities exceeding $5 million.
- Revenue Concentration: Review customer concentration risks; two customers accounted for 60% of revenue in Q1 2025 (Customer A: 25%, Customer B: 35%).
- Dilution Risk: Assess the impact of outstanding warrants (3.9 million) and options (60,000) on future equity dilution.
- Inventory Valuation: Note the $208,737 inventory write-down due to obsolescence recorded as of September 30, 2025.